Exchange: NASDAQ·Updated 04:41 PM EDT
UNCY logo

UNCY Unicycive Therapeutics Inc

$5.16
$0.14
(2.64%)
Today
Closed $5.16
$0.002
(0.04%)
After Hours
Reported EarningsAug 12
Mkt Cap$147.63M
Vol492,855.00

About UNCY

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
55

Bullish Sentiment

How do you feel about UNCY?

Advertisement|Remove ads.